TNXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tonix Pharmaceuticals (TNXP) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company's insider buying activity, positive analyst rating with a significant price target increase, and promising pipeline in underserved markets like fibromyalgia and Lyme disease prophylaxis present strong long-term growth potential. While technical indicators are mixed, the stock's current price and potential catalysts make it an attractive entry point.
The MACD histogram is positive and expanding (0.0929), indicating bullish momentum. RSI is neutral at 56.911, suggesting no overbought or oversold conditions. However, moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a longer-term downtrend. Key support is at 10.367, and resistance is at 12.537.
Insider buying activity has increased by 1801.93% over the last month.
Analysts have initiated a Buy rating with a $22 price target, citing strong potential in fibromyalgia and Lyme disease prophylaxis.
The stock has an 80% chance of gaining 2.45% in the next week.
No recent news to act as a short-term catalyst.
Bearish moving averages indicate potential resistance in the short term.
Stock trend analysis predicts a potential -8.71% drop in the next month.
No financial data available for analysis.
TD Cowen initiated coverage with a Buy rating and a $22 price target. Analysts are optimistic about Tonmya's potential in fibromyalgia and TNX-4800's opportunity in Lyme disease prophylaxis, targeting a large and underserved market with significant sales potential.
